Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Gliosarcoma Market Intelligence Report 2026-2030 & 2035: Expansion of Molecular Testing and Increased Research Funding is Driving Industry Growth

globenewswire.com
NVCR Novocure Ltd. received FDA approval for new electrode arrays used with Optune Gio, enhancing glioblastoma treatment. This innovation suggests positive progress and potential market impact. MRK Merck & Co. Inc.'s acquisition of Modifi Biosciences for $1.3 billion enhances its portfolio in glioblastoma and cancer therapies, indicating strategic growth and investment in advanced treatments. PFE Pfizer Inc. is mentioned as a prominent player in the gliosarcoma market, indicating its presence and potential involvement in the industry's growth, but no specific positive or negative news is provided. ABBV AbbVie Inc. is listed as a key company in the gliosarcoma market. The article does not provide specific details about its performance or recent activities related to this market.

Gliosarcoma Market Intelligence Report 2026-2030 & 2035: Expansion of Molecular Testing and Increased Research Funding is Driving Industry Growth Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Gliosarcoma Market Report 2026" has been added to ResearchAndMarkets.com's offering.

The report provides comprehensive insights, covering global market size, regional shares, market trends, and strategic opportunities for stakeholders.

The gliosarcoma market has experienced notable expansion in recent years, with a projected growth from $1.25 billion in 2025 to $1.32 billion in 2026, at a compound annual growth rate (CAGR) of 5.3%. This growth is underpinned by limited clinical understanding, advances in neuro-pathology, the growth of oncology research institutes, improved imaging technologies, and enhanced academic research interests.

Looking ahead, strong growth is anticipated as the market climbs to $1.6 billion by 2030, at a 5% CAGR. Key drivers include increased funding for rare cancer research, precision diagnostics development, refined treatment protocols, molecular testing expansion, and heightened research center collaborations. Trends projected for this period involve expanded research on rare brain tumors, molecular diagnostics advancements, and the refinement of multimodal treatment strategies, alongside improved diagnostic accuracy.

The rising incidence of brain tumors is expected to further drive market growth. Enhanced diagnostic technologies, greater awareness, and lifestyle factors contributing to risk exposure have led to an increase in brain tumor incidences. Effective gliosarcoma treatment is critical for managing symptoms and improving patients' quality of life. The increasing incidence emphasizes the necessity of these treatments, demonstrated by data from Dementia Australia, which shows a steep rise in dementia cases, indicative of broader neuro-oncological challenges.

Leading companies in the sector are embracing advanced technological solutions, such as wearable devices, for health monitoring and patient engagement. For example, in November 2024, Novocure Ltd. secured FDA approval for new Head Flexible Electrode (HFE) transducer arrays used with Optune Gio, enhancing glioblastoma multiforme (GBM) treatment through Tumor Treating Fields (TTFields) technology. These innovations underscore the commitment to improving patient outcomes.

Strategic acquisitions, such as Merck & Co. Inc.'s $1.3 billion acquisition of Modifi Biosciences in October 2024, enhance portfolios in glioblastoma and broader cancer therapies, showcasing industry moves towards advanced treatments. Prominent market players include Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, and others, highlighting a competitive landscape focused on innovation and patient care.

Regionally, North America was the largest market in 2025, with Asia-Pacific poised as the fastest-growing region through the forecast period. The market encompasses diverse geographies such as Western and Eastern Europe, South America, and numerous emerging markets in Asia and Africa. As the industry adapts to challenges like tariffs affecting import costs, domestic innovation in diagnostics gains momentum, supporting localized advancements.

Reasons to Purchase:

Report Scope

Markets Covered:

Subsegments:

Countries Covered: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Regions: Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Time Series: Five years historic and ten years forecast data.

Data and Segmentation: Consists of market size ratios, growth related to GDP proportions, expenditure per capita, and country and regional historic and forecast data. Includes market share of competitors and segmentation.

Key Attributes

The companies featured in this Gliosarcoma market report include:

For more information about this report visit https://www.researchandmarkets.com/r/4qnkzx

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment